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Abstract 
Antisense oligonucleotides (ONs) have proven useful for selective inhibition of gene expression. However, their effective use is 
limited by inefficient cellular uptake and lack of cellular targeting. In this paper, we report a drug targeting system which utilizes 
mannose receptor-mediated endocytosis to enhance cellular uptake of ONs in alveolar macrophages (AMs). The system employs a 
molecular complex consisting of partially substituted mannosylated poly(L-lysine) (MPL), electrostatically inked to a 5' fluorescently 
labeled ON. Upon recognition by the macrophage mannose receptors, the MPL was internalized by the receptor-mediated pathway, 
co-transporting the ON. Our results indicated that the AMs treated with the MPL:ON complex exhibited a significant increase in ON 
uptake (up to 17-fold) over free ON-treated controls. Effective ON uptake was shown to require the recognition of the mannose moiety 
since unmodified polylysine was much less effective in promoting ON uptake. Specific internalization of the ON:MPL complex by the 
mannose receptor pathway was verified by competitive inhibition using mannosylated albumin. Under this condition, the ON complex 
uptake was inhibited. The requirement of mannose receptors for complex uptake was further demonstrated using a macrophage c ll line, 
J774.1, which expresses a low level of mannose receptors. When treated with the complex, these cells showed no susceptibility to ON 
uptake, thus suggesting the targeting ability of the cartier system to the AMs. Following cellular internalization, the ON complex 
appeared largely accumulated in endocytic vesicles. Enhanced endosomal exit of the ON was achieved using a fusogenic peptide derived 
from the amino terminal sequence of influenza virus hemagglutinin HA2. Cytotoxicity studies showed that at the concentrations 
effectively enhancing ON uptake, both MPL and the fusogenic peptide caused no toxic effects to the cells, thereby suggesting their 
potential safety and utilization in vivo. 
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I. Introduction 
Antisense oligonucleotides have been successfully used 
to inhibit virus or cellular gene expression by forming 
hybrids with mRNAs or DNAs (for review see: [1,2]). Due 
to their exquisite specificity, these compounds are less 
likely to cause undesirable side effects and therefore repre- 
sent a substantial improvement over conventional drugs. A 
major limitation for the effective use of ONs as therapeutic 
agents is their low cellular uptake and lack of cellular 
Abbreviations: AM, alveolar macrophage; BSA, bovine serum albu- 
min; Hepes, N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid; MPL, 
mannosylated polylysine; ON, oligonucleotide; PBS, phosphate-buffered 
saline; PL, poly(L-lysine). 
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targeting. ONs have been shown to be taken up by cells 
through a saturable and energy-dependent process [3,4]. 
However, such a process is relatively inefficient and there- 
fore a relatively high concentration of the compounds is 
generally required to exert pharmacological ctions. 
Several methods have been proposed to increase cellu- 
lar uptake of ONs. Substitution of the compounds with 
lipophilic molecules uch as cholesterol [5,6], acridine [7], 
or alkyl groups [8,9], or association with liposomes [10,11] 
or polycations such as poly(L-lysine) [12,13] has been 
shown to increase cellular uptake and biological activities 
of ONs. However, their effective use in vivo will require a 
more specific method of delivery which can selectively 
deliver ONs to a target cell population. 
Receptor-mediated ndocytosis offers the potential to 
target selected cell types and enhance their uptake. This 
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method has successfully been used to transfer genes [14- 
16] and antisense ONs in selected cells [17-20]. For 
example, asialoorosomucoid-polylysine conjugates have 
been used to target ONs to HepG2 and CAT cells [17,18]. 
Similarly, transferrin and folic acid conjugates have been 
employed to aid cellular delivery of antisense ONs in 
HL-60 cells [19,20]. Macrophages possess mannose- 
specific membrane receptors which can recognize and 
internalize glycoproteins bearing mannose residues [21,22]. 
On this basis, mannosylated glycoproteins could poten- 
tially be used to target and enhance ON uptake by the 
macrophages. Targeted elivery of several cytotoxic drugs 
and antiviral agents by glycoproteins specific to 
macrophages has been previously demonstrated [23,24]. 
Moreover, 6-phosphomannosylated glycoproteins have also 
been used to target antisense ONs to peritoneal 
macrophages [25]. 
Because alveolar macrophages (AMs) play a key role in 
the pathogenesis of several ung diseases and are the host 
of many inhaled pathogens, we decided to target ONs 
using the MPL complex system. To achieve ON delivery, 
the ON-binding polylysine (PL) was partially substituted 
with mannose residues and allowed to form a complex 
with ON. Our results indicated that such complex was 
efficiently and selectively taken up by the AMs, although 
the internalized complex was found mainly associated with 
endocytic vesicles. Since effective antisense activity will 
depend on the ability of the ON to exit these vesicles in 
order to reach its target site in the cytosol, we also tested 
the effect of an endosomal destabilizing peptide derived 
from the influenza hemagglutinin HA2 [26], on uptake and 
intracellular distribution of ON. The HA2 peptide has been 
shown to mediate fusion of viral and endosomal mem- 
branes [27]. This peptide changes conformation at acidic 
pH and destabilizes endosomal membranes, allowing leak- 
age of endosomal contents into the cytosol. Synthetic HA2 
peptide has also been reported to facilitate cytoplasmic 
delivery of genes and ONs [28]. In this study, we also 
found that this peptide can facilitate endosomal exit and 
cytoplasmic delivery of ON in AMs. 
2. Materials and methods 
2.1. Chemicals 
4-Isothiocyanatophenyl-c~-D-mannoside, poly(L-lysine) 
(hydrobromide, Mr = 50 000), rhodamine-labeled poly(L- 
lysine), bovine serum albumin (BSA), and mannosylated 
BSA were obtained from Sigma (St. Louis, MO). 5'- 
BODIPY FL labeled, 18-mer, phosphodiester ON 
(TGTAAAACGACGGCCAGT) and propidium iodide 
were obtained from Molecular Probes (Eugene, OR). The 
labeled ON was purified by HPLC and was > 98% pure. 
The BODIPY label was used in this study because of its 
high fluorescence intensity and pH-insensitive property. 
The fusogenic peptide with the sequence GLFEAIAG- 
FIENGWEGMIDGGGYC was synthesized by Synpep 
(Dublin, CA) using the Fmoc procedure. The peptide was 
purified by HPLC and characterized by amino acid analy- 
sis and mass spectrometry (M + H+: 2506). 
2.2. Synthesis of  mannosylated polylysine 
Mannosylated polylysine was prepared according to the 
method previously described [29]. Briefly, polylysine (0.25 
/xmol) was dissolved in 0.15 M NaCI solution. The pH of 
the solution was adjusted to 9 using 0.1 M NaOH. 4-Iso- 
thiocyanatophenyl-a-o-mannoside (12.5 /zmol) was added 
in small portions to the magnetically stirred protein solu- 
tion. After a 6-h reaction, the resulting solution was refrig- 
erated overnight, and on the following day the pH was 
adjusted to 7.0. Unreacted mannoside and polylysine were 
removed by centrifugal filtration through a dialysis mem- 
brane filter (Durapore TM CL3 K, Millipore) at 5000 × g for 
30 min. 
2.3. Determination of  sugar content 
Sugar content was determined by the rescorcinol sulfu- 
ric method [30] and the protein content was determined by 
micro Lowry assay. Percentage of sugar in mannosylated 
polylysine was determined using the equation: 
X% =- nMo/ ( M p +nM)  
Where n is the number of mannose residues per polyly- 
sine molecule and M o, Mp, and M are the molecular 
weights of mannose, polylysine, and isothiocyanatophenyl 
mannoside, respectively. It was determined that our man- 
nosylated polylysine contained about 50 mannose residues 
per polylysine molecule. 
2.4. Alveolar macrophage preparation 
The AMs were harvested from male Sprague-Dawley 
rats (200-250 g) by broncho-alveolar lavage. Rats were 
anesthetized by intraperitoneal injection of sodium pento- 
barbital (0.2 g/kg body weight). The trachea was cannu- 
lated and the lungs lavaged 10 times with 8-ml aliquots of 
Ca 2+- and MgZ+-free Hank's balanced salt solution (145 
mM NaC1, 5 mM KCI, 1.9 mM NaH2PO 4, 5.5 mM 
glucose, pH 7.4). Lavaged cell suspensions were cen- 
trifuged at 500 × g for 10 min at 4°C. The cell pellets 
were washed twice by alternate resuspension and centrif- 
ugation in Hepes-buffered medium (136 mM NaCI, 2.2 
mM Na:HPO 4, 5.3 mM KC1, 10 mM Hepes, 5.6 mM 
glucose, 1.0 mM CaCI2, pH 7.4). Cell number and purity 
of the macrophage preparations were determined using a 
Coulter electronic ell counter with a cell sizing attach- 
ment (Coulter Instrument, Hialeah, FL). The average val- 
ues for yield and purity were (6.2 _+ 0.3). 106 cells/rat 
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and 92.5 _+ 0.4%, respectively. Cell viability, measured via 
trypan blue exclusion, was > 95%. Aliquots of 0.1 ml 
containing 105 cells were added onto a 96-well plate 
(Costar, Cambridge, MA) and incubated at 37°C in a 
humidified atmosphere at 5% CO 2. 
2.5. Cell culture 
J774.1 cells were cultured in DMEM medium supple- 
mented with 10% fetal bovine serum, 100 units/ml peni- 
cillin, and 0.1 /xg/ml streptomycin. They were maintained 
at 37°C in a humidified atmosphere containing 5% CO 2. 
Prior to use, the cells were washed and resuspended in
Hepes buffer medium. 
2.6. Formation of oligonucleotide-mannosylated polylysine 
complex 
In a typical experiment, he complex was prepared by 
adding 25 /~1 of 50 /xg/ml MPL to 25 /zl of 50 /~g/ml 
ON in Hepes buffer for 30 rain prior to use. In studies 
designed to evaluate the effect of concentration of MPL on 
ON uptake, various concentrations of MPL (0-30/~g/ml)  
were used. The solubility of the complex was monitored 
by determining the fluorescence intensity of the solution 
mixture. Excessive amount of MPL (> 30 /xg/ml) was 
found to cause precipitation of the ON complex as indi- 
cated by the reduction in fluorescence intensity of the 
solution mixture and by microscopic observations. There- 
fore, only MPL with concentrations of < 30 /xg/ml was 
used in this study. In a separate study, the stability of ON 
and ON:MPL complex was studied in a serum-free 
Hepes-buffered medium using gel electrophoresis. After a 
4-h incubation at 37°C, no detectable degradative products 
of ONs were observed. 
2.7. Cellular uptake studies 
2.8. Fluorescence microscopy 
Cells (105/ml) were plated on a glass cover slip. After 
l-h incubation, the cells were washed with Hepes buffer to 
remove unattached cells. The solution containing ON:MPL 
complex (25:25 /~g/ml) was added onto the cells and 
incubated for 1-2 h at 37°C. In experiments designed to 
examine the fate of ON and MPL during cellular internal- 
ization, BODIPY FL-labeled ON and rhodamine-labeled 
MPL were used to form the complex. After incubation, the 
cells were washed, mounted, and examined under a fluo- 
rescence microscope at the excitation/emission wave- 
lengths of 490/520 nm and 560/600 nm, respectively. 
2.9. Cytotoxicity studies 
Following cellular uptake studies, the cells were incu- 
bated at 37°C for 10 min in Hepes buffer containing 1 
/xg/ml propidium iodide. Cellular propidium iodide inten- 
sities were then measured at the excitation and emission 
wavelengths of 490 nm and 600 nm respectively. Cellular 
damage was calculated according to the equation: 
% Damaged Cells 
Measured signal - Minimum signal 
= x 100% 
Maximum signal - Minimum signal 
The maximum signal is the fluorescence signal obtained 
in the presence of Triton X-IO0 (0.1%) which was used to 
permeabilize the cells. The minimum signal is the back- 
ground autofluorescence signal. 
3. Resu l t s  
3.1. Mannosylated polylysine-mediated cellular uptake of 
oligonucleotide 
Cells (105/well) were plated on a 96-well plate. After a 
l-h incubation period in Hepes buffer, the plate was 
washed to remove unattached cells. Solutions containing 
ON in the presence or absence of MPL or PL were added 
directly onto the cells and incubated for 1-4 h at 37°C. 
Subsequently, the cells were washed with cold Hepes 
buffer containing excess unlabeled ON and/or MPL or PL 
to remove surface-bound labeled ON. The cells were then 
measured for their fluorescence intensity using a fluores- 
cence microplate reader at the excitation and emission 
wavelengths of 490 nm and 520 nm respectively. For 
competition studies, cells were treated with ON:MPL com- 
plex in the presence of mannosylated BSA (a specific 
competitor for mannose receptors) or BSA (a nonspecific 
competitor). In experiments employing the fusogenic pep- 
tide HA2, cells were incubated with the complex in the 
presence of increasing amounts of the peptide and their 
fluorescence intensity was similarly determined. 
To evaluate the effectiveness of MPL as a drug carrier 
for ON delivery to the AMs, cells were incubated for 1, 2, 
and 4 h with the ON:MPL complex consisting of ON (25 
/zg/ml) and MPL (25 /~g/ml), after which their fluores- 
cence intensity was measured. As controls, cells were also 
treated with ON alone (25 /xg/ml) or complexed with PL 
(25 /zg/ml), and their fluorescence intensities were simi- 
larly determined. The results indicated that exposure of the 
cells to ON:MPL complex resulted in a significantly higher 
fluorescence intensity over the control levels (Fig. l). The 
enhancing effect was found to be time-dependent, i.e., a 
11-, 14-, and 17-fold increase in fluorescence intensity 
over the ON control after 1, 2, and 4 h respectively. Thus, 
our results demonstrated that the MPL can greatly promote 
cellular uptake of ON and that ON alone was poorly taken 
up by the cells. As can be seen from Fig. l, PL can also 
increase cellular uptake of ON, however, this effect was 
much less pronounced than that caused by MPL. These 
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Fig. l. Comparison of cellular uptake of free oligonucleotide or oligo- 
nucleotide complexed with polylysine or mannosylated polylysine. 
Macrophages (105 cells per well) were incubated with free ON (25 
/xg/ml)  (A), ON:PL complex (25:25 /xg/ml)  (B), or ON:MPL complex 
(25:25 /zg/ml)  (C) for 1, 2, and 4 h in Hepes-buffered medium at 37°C . 
After incubation, the cells were washed and analyzed for their fluores- 
cence intensity. The data represent mean± S.E. of four measurements 
obtained from different cell preparations. 
results indicated that effective ON uptake mediated by the 
complex requires a functional domain capable of effective 
ON cellular recognition and internalization. The observa- 
tion of the increased cellular uptake of ON by PL may be 
attributed to non-specific adsorptive ndocytosis of the 
ON:PL complex. In this regard, it should be noted that PL 
has been used to aid cellular uptake of a number of 
macromolecules including antisense ONs [12,13]. 
3.2. Dose-dependent cellular uptake of oligonucleotide 
complex 
rhodamine-labeled MPL and cellular uptake of the com- 
plex was monitored. As shown in Fig. 4, both MPL and 
ON appeared to be co-internalized by the macrophages. 
The sites where the ON appeared in the cells corresponded 
well to those occupied by the MPL. 
3.4. Mechanism of oligonucleotide complex uptake 
To test whether the cellular internalization of the 
ON:MPL complex was mediated by the mannose 
receptor-mediated pathway, cellular uptake of the ON:MPL 
complex in the presence of competition for mannose recep- 
tors was carried out. In these experiments, the ON:MPL 
complex was incubated with AMs in the presence of a 
specific mannose receptor competitor, mannosylated BSA, 
and a non-specific ompetitor, BSA. The results indicated 
that cellular uptake of the ON:MPL complex was greatly 
inhibited by mannosylated BSA but not by BSA (Fig. 5), 
thus indicating that ON uptake mediated by MPL occurred 
via the mannose receptor pathway. 
In further confirm the mechanism of ON complex up- 
take and to test the potential targeting ability of the MPL 
system, uptake studies were repeated in a macrophage c ll 
line, J774.1, which expresses a low level of mannose 
receptors [31]. The J774.1 cells were found to exhibit a 
much lower uptake as compared to the AMs (Fig. 5), thus 
confirming the mannose receptor-mediated uptake by the 
AMs. The result also indicates the potential targeting 
ability of the mannosylated carrier system. 
3.5. Cytotoxicity studies 
In an attempt o optimize the uptake condition of the 
ON:MPL complex, complexes containing varying concen- 
trations of MPL were formed and tested for their uptake 
efficiency. Fig. 2 showed that at a fixed concentration of
ON (25 /xg/ml), increasing the amount of MPL (upto 30 
/xg/ml) resulted in a proportional increase in cellular 
fluorescence intensity. These results indicated that cellular 
uptake of the ON mediated by MPL was concentration-de- 
pendent. 
3.3. Fluorescence microscopic studies 
To provide morphologic evidence of MPL-mediated 
ON uptake, fluorescence microscopic studies of cells 
treated with ON:MPL or ON alone were conducted. As 
shown in Fig. 3, cells treated with the complex exhibited a
much stronger fluorescence intensity than those treated 
with free ON. In both cases, however, the internalized ONs 
appeared to be localized in endocytic vesicles, as indicated 
by the punctate fluorescence pattern. To test whether the 
MPL was simultaneously internalized along with the ON 
or become dissociated prior to ON internalization, dual- 
fluorescence microscopic studies were conducted. Com- 
plex was formed between the BODIPY FL-labeled ON and 
A major concern relevant o the application of a drug 
carrier system is its safety. In the present study, we 
evaluated the potential toxicity of the carrier system in 
AMs using propidium iodide assay. The AMs were incu- 
bated for 4 h with ON alone or in combination with MPL, 
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Fig. 2. Effect of mannosylated polylysine concentration on cellular uptake 
of oligonucleotide. Macrophages (105 cells per well) were incubated at 
37°C with ON (25 /xg/ml)  complexed with various concentrations of
MPL (0-30 /xg/ml)  for 4 h. After incubation, the cells were washed and 
analyzed for fluorescence intensity. The values represent mean ± S.E., 
n=4.  
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or MPL or PL alone, after which they were analyzed for 
propidium iodide fluorescence. Propidium iodide, due to 
its hydrophilicity, is normally excluded from the cells, but 
if the membrane is damaged the probe can enter the cell 
and bind specifically to the cell nucleus. Upon binding, its 
fluorescence intensity is strongly enhanced; therefore in- 
tense nuclear fluorescence indicates cell damage and death. 
Our results indicated that except for the PL, none of the 
test agents caused apparent toxic effects to the cells (Fig. 
6). PL caused a slight but significant damage to the cells as 
compared to the non-treated control, i,e., = 3% vs. 1%. 
3.6. Enhanced cytoplasmic delivery of oligonucleotide 
The successful utilization of receptor-mediated endocy- 
tosis as a means to enhance cellular uptake of ONs may be 
limited by ON entrapment in endocytic vesicles. As 
demonstrated arlier, ON uptake via the mannose receptor 
pathway led to the distribution of ON largely confined in 
vesicular compartments. As an effort to promote ndoso- 
mal exit of ON, we examined the effect of the fusogenic 
HA2 peptide on ON uptake and its intracellular distribu- 
tion in the AMs. Our results indicated that the peptide 
greatly facilitated cellular uptake of the ON complex in a 
dose-dependent manner (Fig. 7). At the peptide concentra- 
tion of 10 /zM, the cellular uptake of ON complex in- 
creased by over 10-fold as compared to the non-treated 
control. To test whether this promoting effect was due to 
increased endosomal exit of ON, fluorescence microscopic 
study was also conducted. As can be seen in Fig. 8, the 
peptide induced a more diffuse fluorescence pattern as 
compared to the non-treated control (Fig. 3B). Cell viabil- 
ity assays using propidium iodide also indicated that the 
cells maintained their integrity and that the effect of the 
peptide was not simply due to non-specific plasma mem- 
brane damage. Furthermore, in order to confirm the endo- 
somal fusogenic activity of the peptide, experiment shown 
in Fig. 8 was repeated but with the addition of monensin (1 
/~M). Monensin is a weak base commonly used in endocy- 
tosis studies to neutralize the acidic pH of endosomes. 
Since the fusogenic activity of HA2 peptide requires con- 
formational change at acidic pH, neutralization of the 
Fig. 3. Cellular uptake of free and complexed oligonucleotides. Macrophages were incubated with ON (25 /zg/ml) (A) or ON:MPL complex (25:25 
/zg/ml) (B) at 37°C for 1 h. Images were taken at identical settings. On the right cells viewed under fluorescence microscopy, on the left phase-contrast 
images. 
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Fig. 4. Fluorescence micrographs showing intracellular distribution of oligonucleotide (A) and mannosylated polylysine (B) in alveolar macrophages. Cells 
were treated with ON:MPL complex consisting of BODIPY FL-labeled ON (25/zg/ml)  and rhodamine-labeled MPL (25/xg/ml)  at 37°C for 2 h. Images 
were taken from the same view but at different fluorescence settings as described in Section 2. 
endosomal pH would therefore inhibit its fusogenic activ- 
ity. Indeed, our results indicated that in the presence of 
monensin the cells exhibited a punctate fluorescence pat- 
tern similar to that observed in cells treated with the ON 
complex alone (see Fig. 3B). In the absence of fusogenic 
peptide, monensin had no effect on the fluorescence distri- 
bution of ON. Thus, our results trongly suggested that the 
peptide was co-internalized and exhibited fusogenic activ- 
ity in the endosomes. 
] 
@ 
| 
j 
A B C D 
Fig. 5. Mechanisms of oligonucleotide uptake mediated by mannosylated 
polylysine. Macrophages were incubated with ON:MPL complex (25:25 
/xg/ml) at 37°C for 4 h in the absence (A) or presence of mannosylated 
albumin (1 mg/ml)  (B), as a specific competitor for mannose receptor, or 
albumin (1 mg/ml )  (C), as a non-specific ompetitor. (D) same as (A) 
but J774.1 cells were used. The values represent mean + S.E., n = 4. 
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Fig. 6. Cytotoxicity of oligonucleotide and carrier systems in alveolar 
macrophages. Cells were incubated with (A) blank buffer, (B) free ON 
(25 /.~g/ml), (C) ON:MPL complex (25:25 /zg/ml), (D) MPL alone (25 
/zg/ml), and (E) PL alone (25 /xg/ml) at 37°C for 4 h. The values 
represent mean + S.E., n = 4. * Significant increase over control A (P  < 
0.05). 
W. Liang et al. / Biochimica et Biophysica Acta 1279 (1996) 227-234 233 
30000 
25O00 - 
20000 - 
15000 
10000, 
5000 - 
o I ! I ! I I 
0 2 4 6 8 10 
Peptide Concentration (~M} 
Fig. 7. Effect of fusogenic peptide concentration on cellular uptake of 
oligonucleotide complex. Macrophages were incubated with ON:MPL 
complex (25:25 /xg/ml) in the presence of varying concentrations of
HA2 peptide (0-10 IzM) at 37°C for 4 h. The values represent mean+ 
S.E., n=4.  
Fig. 8. Fluorescence micrograph showing effect of HA2 peptide on 
cellular distribution of oligonucleotide complex. Macrophages were incu- 
bated with ON:MPL complex (25:25 /xg/ml) in the presence of peptide 
(10 /zM) at 37°C for 2 h. 
4. Discussion 
The AM plays an important role in host defense against 
inhaled noxious substances and in pathogenesis of several 
pulmonary diseases. The study of macrophage function 
and regulation as well as its potential therapeutic nterven- 
tion by antisense agents will require the development of
drug delivery systems capable of effective and selective 
transfer of ONs to the AMs. In this study, we have 
demonstrated that receptor-mediated ndocytosis of the 
mannose receptor can be exploited to provide enhanced 
and targeted elivery of ON to the AMs. Polylysine par- 
tially substituted with mannose residues, as the recognition 
signal, gave a soluble complex upon mixing with ON. The 
cellular internalization of the complex was via receptor- 
mediated endocytosis which offers the potential advan- 
tages of improved uptake efficiency and targeting. As 
demonstrated in this study, the cellular uptake of ON 
complexed with MPL was much more efficient han that of 
free ON. The intracellular fluorescence intensity was about 
17-fold higher than that of cells treated with ON alone. 
This enhanced delivery of ON by molecular complex 
should improve the effectiveness of antisense ONs for the 
inhibition of gene expression. 
The uptake of ON:MPL complex was found to be 
mediated by the mannose receptor since (a) the mannose 
receptor binding moiety was required for effective uptake 
of the ON complex, (b) cells bearing few receptors (J774.1 
cell line) did not appreciably take up the complex, and (c) 
competition for mannose receptors by mannosylated BSA 
inhibited the cellular uptake of the complex. 
After internalized by the AMs, the ON:MPL complex 
was localized mainly in endocytic vesicles, as revealed 
from microscopic studies. As biological effects have been 
reported with antisense ONs, it is expected that small 
amounts of the ONs which have been taken up into 
vesicles have escaped the endosomes and reached their 
targets in the cytosol or nucleus. The exit of antisense ONs 
from the lumen of endocytic vesicles to the cytosol could 
take place either in late endosomes, in t rans  Golgi net- 
work, or in Golgi apparatus, although the precise mecha- 
nisms of exit have not been elucidated. The observation 
that certain endosomal disrupting agents uch as fusogenic 
viral peptides can dramatically improve the biological 
activity of ONs [28] suggests that such exit mechanisms 
are rather ineffective. Therefore, the ability to facilitate 
endosomal exit of ONs is an important consideration i
their utilization as therapeutic agents. In this study, we 
tested the endosomal destabilizing effect of HA2 peptide 
and its influence on macrophage uptake and distribution of 
ON. Since mannose receptor-mediated ndocytosis is a 
recycling process [22], enhanced endosomal escape by the 
peptide is expected to result in increased cellular distribu- 
tion of ON. Accordingly, our study showed that in the 
presence of the peptide the cellular uptake of ON:MPL 
was greatly enhanced. Microscopic evidence further sug- 
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gested that this enhancing effect was associated with in- 
creased cytoplasmic entry of the ON complex. 
The application of the complex carrier system for in 
vivo ON delivery remains to be established. The complex 
anatomy of the lung as well as the great variety of existing 
lung cell types may limit the effectiveness of the delivery 
system. However, the targeting ability provided by the 
system should prove beneficial to targeted elivery of ON 
to the AMs. The potential toxicity of the delivery system 
in vivo needs also to be further investigated. Although our 
in vitro studies indicated the relative safety of the system 
for the AMs, other lung cell types may be more sensitive 
to toxicity caused by the system. 
Acknowledgements 
This work is supported in part by the National Institutes 
of Health Grant HL54291 to Y.R. 
References 
[1] Helene, C. and Toulme, J.J. (1990) Biochim. Biophys. Acta 1049, 
99-125. 
[2] Uhlman, E. and Peyman, A. (1990) Chem. Rev. 90, 543-584. 
[3] Loke, S.L., Stein, C.A., Zhang, X.H., Mori, K., Nakanishi, M., 
Subasinghe, C., Cohen, J.S. and Neckers, L.M. (1989) Proc. Natl. 
Acad. Sci. USA 86, 3474-3478. 
[4] Stein, C.A., Mori, K., Loke, S.L., Subasinghe, C., Cohen, J.S. and 
Neckers, L.M. (1988) Gene 72, 333-341. 
[5] Letsinger, R.L., Zhang, G.R., Sun, D.K., Ikeuchi, T. and Sarin, P.S. 
(1989) Proc. Natl. Acad. Sci. USA 86, 6553-6556. 
[6] Boutorin, A.S., Gus'kova, L.V., Ivanova, E.M., Kobetz, N.D., Zary- 
tova, V.F., Ryte, A.S., Yurchenko, L.V. and Vlassov, V.V. (1989) 
FEBS Lett. 254, 129-132. 
[7] Toulme, J.J., Krisch, H.M., Loreau, N., Thuong, N.T. and Helene, 
C. (1986) Proc. Natl. Acad. Sci. USA 83, 1227-1233. 
[8] Kabanov, A.V., Vinogradov, S.V., Ovcharenko, A.V., Krivonos, 
A.V., Melik-Nubarov, N.S., Kiselev, V.I. and Severin, E.S. (1990) 
FEBS Lett. 259, 327-330. 
[9] Saison-Behmoaras, T., Tocque, B., Rey, I., Chassignol, M., Thuong, 
N.T. and Helene, C. (1991) EMBO J. 10, 1111-1118. 
[10] Bennett, F.C., Chiang, M.Y., Chan, H.C., Shoemaker, ].E.E. and 
Mirabelli, C.K. (1992) Mol. Pharmacol. 41, 1023-1033. 
[11] Chu, C.J., Dijkstra, J., Lai, M.Z., Hong, K. and Szoka, F.C. (1990) 
Pharm. Res. 7, 824-834. 
[12] Lemaitre, M., Bayard, B. and Lebleu, B. (1987) Proc. Natl. Acad. 
Sci. USA 84, 648-652. 
[13] Stevenson, M. and Iversen, P. (1989) J. Gen. Virol. 70, 2673-2682. 
[14] Wu, G.Y. and Wu, C.H. (1987) J. Biol. Chem. 262, 4429-4432. 
[15] Wagner, E., Zenke, M., Cotten, M., Beug, H. and Birnstiel, M.L. 
(1990) Proc. Natl. Acad. Sci. USA 87, 3410-3414. 
[16] Rojanasakul, Y., Wang, L.Y., Malanga, C.J., Ma, J.K.H. and Liaw, 
J. (1994) Pharm. Res. 11, 1731-1736. 
[17] Bunnell, B.A., Askari, F.K. and Wilson, J.M. (1992) Som. Cell Mol. 
Gen. 18, 559-569. 
[18] Wu, G.Y. and Wu, C.H. (1992) J. Biol. Chem. 267, 12436-12439. 
[19] Citro, G., Perrotti, D., Cucco, C., D'Agnano, I., Sacchi, A., Zupi, G. 
and Calabretta, B. (1992) Proc. Natl. Acad. Sci. USA 89, 7031-7035. 
[20] Citro, G., Szczylik, C., Ginobbi, P., Zupi, G. and Calabretta, B. 
(1994) Br. J. Cancer 69, 463-467. 
[21] Stahl, P., Rodman, J.S., Miller, M.J. and Schlesinger, P.H. (1978) 
Proc. Natl. Acad. Sci. USA 75, 1399-1403. 
[22] Stahl, P., Schlesinger, P.H., Sigardson, E., Rodman, J.S. and Lee, 
Y.C. (1980) Cell 19, 207-215. 
[23] Roche, A.C., Barzillay, M., Midoux, P., Junqua, S., Sharon, N. and 
Monsigny, M. (1983) J. Cell Biochem. 22, 131-140. 
[24] Duncan, R., Kopeckova-Rejmanova, P., Strohalm, J., Hume, I., 
Cable, H.C., Phol, J., Lloyd, J.B. and Kopecek, J. (1987) Br. J. 
Cancer 55, 165-174. 
[25] Bonfils, E., Depierreux, C., Midoux, P., Thuong, N.T., Monsigny, 
M. and Roche, A.C. (1992) Nucleic Acids Res. 20, 4621-4629. 
[26] Lear, J.D. and DeGrado, W.F. (1987) J. Biol. Chem. 262, 6500- 
6505. 
[27] Wiley, D.C. and Skehel, J.J. (1987) Annu. Rev. Biochem. 56, 
365-394. 
[28] Bongartz, J.P., Aubertin, A.M., Mihaud, P.G. and Lebleu, B. (1994) 
Nucleic Acids Res. 22, 4681-4688. 
[29] McBroom, C.R., Samanen, C.H. and Goldstein, I.J. (1972) Methods 
Enzymol. 28, 212-219. 
[30] Monsigny, M., Petit, C. and Roche, A.C. (1988) Anal. Biochem. 
175, 525-530. 
[31] Stahl, P.D., Wileman, T.E., Diment, S. and Shepherd, V.L. (1984) 
Biol. Cell. 51,215. 
